LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited has achieved a key milestone with SPONTAN® now being prescribed to patients under the TGA Authorised Prescriber Scheme, facilitating broader access to its fast-acting erectile dysfunction nasal spray treatment. The scheme’s approval marks the company’s strategic progression in addressing a significant unmet medical need in men’s health. This development is further bolstered by the involvement of Professor Eric Chung, a leading expert in urology, ensuring expert-led treatment outcomes.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
